Major Gap in the Prostate Cancer Hormone-Refractory Market According to New Report
Posted on: Friday, 8 February 2008, 12:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c82032) has announced the addition of Datamonitor's new report: Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs to their offering.
Introduction
As a result of market dominance by agents such as leuprolide, and AstraZeneca's Zoladex (goserelin) and Casodex (bicalutamide), there is little space in the antihormonal therapies market for new competition unless significant clinical superiority or a unique selling point is demonstrated. While Taxotere-based chemotherapy is the established first-line standard for hormone-refractory prostate cancer, many patients are still precluded from treatment due to toxicity concerns. This, coupled with a lack of second-line standard therapy, indicates a major gap in the market that could be potentially lucrative for drug developers. Enthusiasm has been shown by key opinion leaders regarding certain late-phase pipeline products, however, during the time of writing, publication of negative clinical trial data has meant a dampening of this optimism. It will therefore be some time before the high unmet needs in the hormone-refractory prostate cancer market are satisfied.
Scope
Identify key factors that influence prescribing patterns for systemic therapy of prostate cancer
Examine the significant unmet needs in the prostate cancer market and identify opportunities for new product development
Enhance commercial positioning by increasing understanding of current dynamics within the prostate cancer market
Companies Mentioned:
Abbot Spectrum Pharmaceuticals GPC Biotech Dendreon Cell Genesys Novacea Schering-Plough Northwest Biotherapeutics Genentech Roche
For more information visit http://www.researchandmarkets.com/reports/c82032
Source: Datamonitor
Source: Business Wire
Related Articles
- Prostate Cancer - Hormone-Refractory Patients Still Waiting for Treatment Breakthroughs
- Medivation Announces Treatment of First Patient in Phase 1-2 Clinical Trial of MDV3100 in Hormone-Refractory Prostate Cancer
- Cytogen Announces Initiation of NCI-Sponsored Phase 2 Clinical Trial of QUADRAMET With Targeted Cancer Vaccine for Hormone-Refractory Prostate Cancer
- Medivation's MDV3100 Shown to Be Effective in a Preclinical Model of Hormone-Refractory Prostate Cancer
- Hollis-Eden Pharmaceuticals Presents Positive Preclinical Data on Compounds Targeting Hormone Refractory Prostate Cancer
- Medivation Acquires Novel Compounds to Treat Hormone-Refractory Prostate Cancer
- ARIAD Initiates Phase 2 Clinical Trial of AP23573 in Hormone-Refractory Prostate Cancer; Over 30,000 Deaths From Prostate Cancer Expected in 2005
- FDA Agrees to File Abbott's New Drug Application for Xinlay(TM) (Atrasentan) to Treat Metastatic Hormone-Refractory Prostate Cancer
- Research and Markets: Metastatic and Hormone Refractory Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds